CN112516288B - Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein - Google Patents
Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein Download PDFInfo
- Publication number
- CN112516288B CN112516288B CN202011523442.6A CN202011523442A CN112516288B CN 112516288 B CN112516288 B CN 112516288B CN 202011523442 A CN202011523442 A CN 202011523442A CN 112516288 B CN112516288 B CN 112516288B
- Authority
- CN
- China
- Prior art keywords
- seq
- ganoderma
- ganoderma lucidum
- immunomodulatory protein
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 98
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 72
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 72
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 62
- 230000004988 N-glycosylation Effects 0.000 title claims abstract description 45
- 230000014509 gene expression Effects 0.000 claims abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 11
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 10
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 230000037361 pathway Effects 0.000 claims abstract description 6
- 102220192411 rs749977756 Human genes 0.000 claims description 52
- 102220614767 Ras-related protein Rab-3B_T36N_mutation Human genes 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 21
- 241000235058 Komagataella pastoris Species 0.000 claims description 11
- 241000222336 Ganoderma Species 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 241001489091 Ganoderma sinense Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 4
- 241001149422 Ganoderma applanatum Species 0.000 claims description 4
- 241000906988 Ganoderma atrum Species 0.000 claims description 4
- 241001480606 Ganoderma microsporum Species 0.000 claims description 4
- 241001480597 Ganoderma tsugae Species 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 241001506991 Komagataella phaffii GS115 Species 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 241001489090 Ganoderma japonicum Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 24
- 239000012634 fragment Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 4
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 4
- JZRLLSOWDYUKOK-SRVKXCTJSA-N Asn-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N JZRLLSOWDYUKOK-SRVKXCTJSA-N 0.000 description 4
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 4
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 4
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 4
- UTLCRGFJFSZWAW-OLHMAJIHSA-N Asp-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UTLCRGFJFSZWAW-OLHMAJIHSA-N 0.000 description 4
- BPAUXFVCSYQDQX-JRQIVUDYSA-N Asp-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)N)O BPAUXFVCSYQDQX-JRQIVUDYSA-N 0.000 description 4
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- RNPGPFAVRLERPP-QEJZJMRPSA-N Gln-Trp-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O RNPGPFAVRLERPP-QEJZJMRPSA-N 0.000 description 4
- ZMXZGYLINVNTKH-DZKIICNBSA-N Gln-Val-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZMXZGYLINVNTKH-DZKIICNBSA-N 0.000 description 4
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 description 4
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 4
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 4
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 4
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 4
- WIZPFZKOFZXDQG-HTFCKZLJSA-N Ile-Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O WIZPFZKOFZXDQG-HTFCKZLJSA-N 0.000 description 4
- UYNXBNHVWFNVIN-HJWJTTGWSA-N Ile-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 UYNXBNHVWFNVIN-HJWJTTGWSA-N 0.000 description 4
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 4
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 4
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 4
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 4
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 4
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- GYEPCBNTTRORKW-PCBIJLKTSA-N Phe-Ile-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O GYEPCBNTTRORKW-PCBIJLKTSA-N 0.000 description 4
- KDYPMIZMXDECSU-JYJNAYRXSA-N Phe-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KDYPMIZMXDECSU-JYJNAYRXSA-N 0.000 description 4
- ZVRJWDUPIDMHDN-ULQDDVLXSA-N Phe-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 ZVRJWDUPIDMHDN-ULQDDVLXSA-N 0.000 description 4
- RETPETNFPLNLRV-JYJNAYRXSA-N Pro-Asn-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O RETPETNFPLNLRV-JYJNAYRXSA-N 0.000 description 4
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 4
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 4
- DXYWRYQRKPIGGU-BPNCWPANSA-N Tyr-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DXYWRYQRKPIGGU-BPNCWPANSA-N 0.000 description 4
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 4
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 4
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 4
- 108010044940 alanylglutamine Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 108010047857 aspartylglycine Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 4
- 108010017391 lysylvaline Proteins 0.000 description 4
- 108010038745 tryptophylglycine Proteins 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- JTXVXGXTRXMOFJ-FXQIFTODSA-N Asn-Pro-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O JTXVXGXTRXMOFJ-FXQIFTODSA-N 0.000 description 2
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 2
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150102326 1.1 gene Proteins 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Plant Pathology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
Abstract
The application of the N-glycosylation modified ganoderma lucidum immunomodulatory protein reduces the expression of proinflammatory mediators by inhibiting a p38 MAPK pathway, improves the expression of the anti-inflammatory mediators at the same time, has higher biological activity and lower cytotoxicity and shows more obvious anti-inflammatory activity.
Description
Technical Field
The invention relates to a technology in the field of biological pharmacy, in particular to an application of an N-glycosylation modified ganoderma lucidum immunomodulatory protein.
Background
Macrophages, as a cell population with plasticity and pluripotency, exhibit significant functional differences under the influence of different microenvironments in vivo and in vitro. At present, macrophages are classified into M1 type, i.e., classically activated macrophages, and M2 type, i.e., alternatively activated macrophages, according to their activation state and function. M1-type macrophages are triggered in response to pro-inflammatory cytokines and pathogen-associated molecular patterns (PAMPs) such as interferon gamma (IFN-gamma) and LPS. This type of macrophage produces cytotoxic and inflammatory molecules such as Nitric Oxide (NO) and Reactive Oxygen Species (ROS), proinflammatory cytokines such as tumor necrosis factor (TNF- α), interleukin (IL) -1 β and IL-6, chemokines such as monocyte chemoattractant protein-1 (MCP-1/CCL-2), and the like. M2-type macrophages are primarily responsible for anti-inflammatory cytokines, parasite infection and injury associated molecular patterns (DAMPs) such as IL-4 and IL-13, and play an important role in inhibiting acute and chronic inflammatory responses and tissue repair. M2-type macrophages are capable of secreting large amounts of anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta (TGF-. Beta.). The Ganoderma lucidum immunomodulatory protein is a bioactive protein existing in Ganoderma lucidum (Ganoderma lucidum), and has immunoregulatory function. It is disclosed in the prior art that ganoderma immunomodulatory protein is capable of activating macrophages while promoting the production of pro-inflammatory and anti-inflammatory mediators. However, proinflammatory mediators tend to be the cause of chronic inflammation.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the application of the N-glycosylation modified ganoderma lucidum immunomodulatory protein, which can reduce the expression of proinflammatory mediators by inhibiting a p38 MAPK pathway and improve the expression of the proinflammatory mediators at the same time.
The invention is realized by the following technical scheme:
the invention relates to application of N-glycosylation modified ganoderma lucidum immunomodulatory protein in preparation of an anti-inflammatory drug for inhibiting a p38 MAPK pathway in cells and reducing expression of proinflammatory mediators.
The amino acid sequence of the N-glycosylation modified ganoderma lucidum immunomodulatory protein is shown as Seq ID No.1, seq ID No.2 and Seq ID No.3, and preferably: seq ID No.3.
The cells comprise mouse peritoneal macrophage RAW264.7.
The anti-inflammatory drug is a composition, a nutritional supplement, a food additive, a functional food supplement or a functional beverage composition, and comprises the N-glycosylation modified ganoderma lucidum immunomodulatory protein.
The invention relates to a preparation method of the ganoderma lucidum immunomodulatory protein modified by N-glycosylation, which is characterized in that based on the amino acid sequence of the ganoderma lucidum immunomodulatory protein shown in Seq ID No.17, the gene synthesis is carried out by referring to pichia pastoris (Pichia pastoris) preference codon shown in Seq ID No.18, and the primer shown in Seq ID No. 4-7 is used for obtaining the N31S gene of the ganoderma lucidum immunomodulatory protein modified by N-glycosylation shown in Seq ID No. 19; or obtaining the N-glycosylation modified ganoderma lucidum immunomodulatory protein T36N gene shown in the Seq ID No.20 through primers shown in the Seq ID No.4, seq ID No.8, seq ID No.9 and Seq ID No. 7; or obtaining the N-glycosylation modified ganoderma lucidum immunomodulatory protein N31S/T36N gene shown in the sequence ID No.21 through primers shown in the sequence ID No.4, the sequence ID No.5, the sequence ID No.10 and the sequence ID No. 7. The N31S gene, the T36N gene and the N31S/T36N gene are respectively cloned to a eukaryotic expression vector pPIC 9K: X-His, and then the Pichia pastoris GS115 is respectively transformed to obtain yeast transformants, and finally the recombinant protein is obtained through methanol induction.
The primer is specifically as follows: seq ID No.4:5 'ccgccgccggaaattcatgtctgacacaccgcttttgatctc-3', seq ID No.5:5 'gaagttagatggttaccctttccc-3', seq ID No.6:5 'gggaaggtaacccatctataactttcatcacaaag-3', seq ID No.7:5 'atgatgatgggccgtccattgagcaatgatgaagtcg-3', seq ID No.8:5 'gaagttgtttgggttaccctttccc-3', seq ID No.9:5 'gggaaggtaacccaaacaacttcatcatcgacaacaacgttaccttccccaaag-3', seq ID No.10:5 'gggaaggtaaccctacttcatcatcaacgttaccctcccaaag-3'.
The Ganoderma lucidum immunomodulatory protein is selected from Ganoderma lucidum (Ganoderma lucidum), ganoderma tsugae (Ganoderma tsugae), ganoderma sinense (Ganoderma japonica), ganoderma microsporum (Ganoderma microsporum), ganoderma sinense (Ganoderma sinensis), ganoderma atrum (Ganoderma atrum), ganoderma applanatum (Ganoderma applanatum) and Ganoderma pseudoantler (Ganoderma amboinense), and preferably Ganoderma lucidum (Ganoderma lucidum).
The amino acid sequence of the ganoderma lucidum immunomodulatory protein is preferably Genbank: the sequence shown in LZ8_ GANLU is shown in detail in Seq ID No. 17.
The N-glycosylation modified ganoderma lucidum immunomodulatory protein is derived from a eukaryotic expression system, preferably a pichia pastoris expression system.
Technical effects
The invention obtains the N-glycosylation modified ganoderma lucidum immunomodulatory protein by modifying the ganoderma lucidum immunomodulatory protein; the N-glycosylation modified ganoderma lucidum immunomodulatory protein has an anti-inflammatory effect, and the effect is realized by inhibiting a p38 MAPK pathway. Compared with the prior art, the N-glycosylation modified ganoderma lucidum immunomodulatory protein has higher biological activity, lower cytotoxicity and more obvious anti-inflammatory activity.
Drawings
FIG. 1 is a nucleic acid electrophoresis diagram showing the acquisition of N-glycosylation modified genes of immunomodulatory proteins (N31S, T36N and N31S/T36N) of Ganoderma lucidum;
in FIG. 1A, lane 1 is the fragment N31S _ F1, lane 2 is the fragment N31S _ F2, lane 3 is the fragment T36N _ F1, lane 4 is the fragment T36N _ F2, lane 5 is the fragment N31S/T36N _ F1, lane 6 is the fragment N31S/T36N _ F2, lane M is DNA Marker DL 2, 000 (TaKaRa Biotechnology (Beijing) Ltd.). In FIG. 1B, lane 1 is the N31S gene, lane 2 is the T36N gene, lane 3 is the N31S/T36N gene, lane M is the DNA Marker DL 2, 000;
FIG. 2 is a graph showing the expression of ganoderma lucidum immunomodulatory protein and N-glycosylation modified ganoderma lucidum immunomodulatory protein;
in the figure: a is an SDS-PAGE detection image, and B is a Western Blot detection image. Lane M is the protein standard molecular weight (shanghai bi yunnan biotechnology limited), lane 1 shows ganoderma lucidum immunomodulatory protein WT; lane 2 shows N-glycosylation modified Ganoderma immunomodulatory protein N31S, lane 3 shows N-glycosylation modified Ganoderma immunomodulatory protein T36N, and lane 4 shows N-glycosylation modified Ganoderma immunomodulatory protein N31S/T36N;
FIG. 3 is a graph showing the relative amount of inflammatory mediator gene expression in examples;
the figure shows the effect of N-glycosylation modified ganoderma lucidum immunomodulatory protein on expression of pro-inflammatory mediator genes and anti-inflammatory mediator genes;
FIG. 4 is a schematic of Western Blot of the p38 MAPK pathway;
the anti-inflammatory mechanism of action of the N-glycosylation modified immunomodulatory proteins of Ganoderma lucidum is shown.
Detailed Description
Specific materials of the following examples include:
1. the strain is as follows: e.coli DH 5. Alpha.; pichia pastoris GS115.
2. Animal cells: mouse abdominal macrophage RAW264.7 purchased from cell bank of Shanghai Life sciences research institute of Chinese academy of sciences. The culture method comprises the following steps: mouse peritoneal macrophage RAW264.7 was washed with PBS, trypsinized, and the cells were suspended in DMEM cell culture medium. Count cells at 2X 10 5 At a concentration of one/mL, cells were inoculated into a new cell culture flask containing DMEM medium and placed in CO 2 The incubator was incubated at 37 ℃.
3. The kit comprises:AxyPrep TM plasmid Miniprep Kit and @>AxyPrep TM DNA Gel Extraction Kit, available from Kangning Life sciences (Wujiang) Ltd; t4 DNA Ligase, miniBEST Universal RNA Extraction Kit and PrimeScript TM RT Master Mix (Perfect Real Time) was purchased from TaKaRa Biotechnology (Beijing) Ltd; aceQ Universal SYBR qPCR Master Mix, available from Sorbon Kinzau Biotech, inc.; the BCA method protein concentration determination kit is purchased from Biotechnology engineering (Shanghai) Co., ltd.
4. Enzymes: 2 × TSINGKE Master Mix (blue), available from seiko biotechnology limited of kyoto; restriction enzymes EcoR I, apa I and Sac I, available from TaKaRa Biotechnology, beijing, inc.
Example 1
The preparation of the N-glycosylation modified ganoderma lucidum immunomodulatory protein specifically comprises the following steps:
1.1 Gene Synthesis
According to the amino acid sequence (Genbank: LZ8_ GANLU) of Ganoderma lucidum immunomodulatory protein from Ganoderma lucidum (Ganoderma lucidum), performing sequence synthesis by referring to Pichia pastoris (Pichia pastoris) preferred codon to obtain a synthetic sequence shown as Seq ID No.35, constructing the synthetic sequence on a cloning vector pUC-57, transforming to Escherichia coli strain DH5 alpha, and extracting plasmid.
This example refers to the Ganoderma lucidum immunomodulatory protein from Ganoderma lucidum (Ganoderma lucidum) as WT, the original Ganoderma lucidum immunomodulatory protein.
1.2 cloning of mutant genes
Carrying out PCR reaction by taking the plasmid in 1.1 as a template, which specifically comprises the following steps: carrying out conventional PCR reaction by respectively taking a primer sequence P1 shown in Seq ID No.4, a primer sequence P2 shown in Seq ID No.5, a primer sequence P3 shown in Seq ID No.6 and a primer sequence P4 shown in Seq ID No.7 as primers to obtain two fragments N31S _ F1 and N31S _ F2 of the N31S gene of the N-glycosylation modified ganoderma lucidum immunomodulatory protein; carrying out conventional PCR reaction by respectively taking a primer sequence P1 shown in Seq ID No.4, a primer sequence P5 shown in Seq ID No.8, a primer sequence P6 shown in Seq ID No.9 and a primer sequence P4 shown in Seq ID No.7 as primers to obtain two fragments T36N _ F1 and T36N _ F2 of the N-glycosylation modified ganoderma lucidum immunomodulatory protein T36N gene; a conventional PCR reaction was carried out using the primer sequences P1 and P2 shown in Seq ID No.4 and P7 shown in Seq ID No.10 and P4 shown in Seq ID No.7 as primers, respectively, to obtain two fragments N31S/T36N _ F1 and N31S/T36N _ F2 of the N31S/T36N gene of N-glycosylation modified Ganoderma lucidum immunomodulatory protein (FIG. 1A).
After purifying the above gene fragments, N31S _ F1 and N31S _ F2, T36N _ F1 and T36N _ F2, and N31S/T36N _ F1 and N31S/T36N _ F2 are used as primers and templates, respectively, to perform conventional PCR reactions, thereby obtaining N31S, T36N, and N31S/T36N genes, respectively (FIG. 1B).
1.3 obtaining of Yeast transformants: the laboratory constructed plasmid pPIC 9K: X-His as well as the WT gene obtained in 1.1 and the N31S, T36N and N31S/T36N genes obtained in 1.2 were digested with the restriction enzymes EcoR I and Apa I at 37 ℃ for 2h according to the following digestion system.
SaidThe enzyme cutting system is as follows: 20 μ L of buffer, 3 μ L of EcoR I, 3 μ LApa I, 20 μ L of DNA (plasmid pPIC 9K: X-His and genes WT, N31S, T36N and N31S/T36N, respectively), 154 μ L of dH 2 O。
1.4 the digestion products were separated by electrophoresis on a 1% agarose gel in 1 XTAE electrophoresis buffer, stained with ethidium bromide, photographed using a gel imaging system and the linearized vector pPIC 9K: his as well as the WT, N31S, T36N and N31S/T36N gene fragments were recovered. The WT, N31S, T36N, and N31S/T36N gene fragments were ligated with the linearized vector pPIC 9K: his, respectively, according to conventional reaction protocols to construct the recombinant expression plasmids pPIC 9K: WT-His, pPIC 9K: N31S-His, pPIC 9K: T36N-His, and pPIC 9K: N31S/T36N-His.
1.5 the ligation product was transformed into E.coli DH 5. Alpha. The plasmids pPIC 9K: WT-His, pPIC 9K: respectively
N31S-His, pPIC 9K: T36N-His and pPIC 9K: N31S/T36N-His, were digested with the restriction enzyme Sac I for 2h at 37 ℃. And recovering the enzyme digestion product, and then carrying out yeast transformation to obtain a yeast transformant.
The yeast transformation comprises the following steps:
1.5.1 Pichia pastoris monoclonal was picked, cultured in YPD liquid medium at 30 ℃ at 220rpm with shaking to OD 600 0.8 to 1.0;
1.5.2 ) at 1, 500 Xg room temperature for 10min, harvest cells, with 25mL sterile water washing, and the same conditions of centrifugation, abandon the supernatant, with the 1mL 100mM LiCl heavy suspension cells;
1.5.3 Transfer the cell suspension to a 1.5mL centrifuge tube, centrifuge at maximum speed for 15s, remove LiCl;
1.5.4 Resuspend the cells with 400. Mu.L of 100mM LiCl and dispense 50. Mu.L of the cell suspension into 1.5mL centrifuge tubes;
1.5.5 Boiling single-stranded DNA for 5min and then rapidly putting into ice;
1.5.6 ) centrifuging the cell suspension to remove LiCl;
1.5.7 mu.L 50% PEG, 36. Mu.L LiCl at a concentration of 1M, 50. Mu.g of single-stranded DNA, and 10. Mu.g of plasmid DNA were added in this order.
1.5.8 After resuspending the cells, the cells were cultured at room temperature for 30min;
1.5.9 Heat shock at 42 ℃ for 20-25 min;
1.5.10 Centrifuging at 6,000-8,000 rpm, discarding the transformation solution, and resuspending with 1mL of sterile water;
1.5.11 ) applying appropriate amount of suspension to MD Kan Culturing on solid culture medium at 30 deg.C for 2-4 days.
1.6 expression and purification of recombinant proteins: selecting yeast transformant to be monoclonal to BMGY liquid culture medium, and carrying out shaking culture at 30 ℃ and 220rpm until OD600 is 2-6; centrifugation at 2, 500 × g for 5min at room temperature to collect cells, supernatant was removed, and cells were resuspended in BMMY liquid medium to an OD600 of 1.0; four days in culture, pure MeOH was added daily to BMMY broth to a final concentration of 1% (V/V).
1.7 at room temperature with 2, 500 Xg centrifugal 5min to collect the supernatant, and the supernatant through 3.5kD dialysis bag dialysis, dialysis bag fluid freeze drying and Lysis Buffer dissolved; his60 Ni Superflow Resin column was equilibrated with 5 volumes of lysine Buffer; loading Lysis Buffer solution; washing with 10 times volume of Wash Buffer; eluting with 2 times volume of Elution Buffer and collecting the eluent; dialyzing the eluate through 3.5kD dialysis bag, freeze-drying the dialysate in the dialysis bag, and dissolving in PBS to obtain PBS solution containing recombinant WT, N31S, T36N and N31S/T36N proteins. The obtained protein solution was subjected to SDS-PAGE and Western Blot detection. The results showed that the resulting protein was the protein of interest (FIG. 2).
Example 2
The anti-inflammatory application of the N-glycosylation modified ganoderma lucidum immunomodulatory protein specifically comprises the following steps:
at 2X 10 5 Cell/well concentration cells were seeded into 24 well cell culture plates and cultured for 24h. The medium was discarded, and medium containing 10. Mu.g/mL of Ganoderma lucidum immunomodulatory protein (WT) and N-glycosylation-modified Ganoderma lucidum immunomodulatory protein (N31S, T36N and N31S/T36N) was added, respectively, and the culture was continued for 6 hours. Total RNA was extracted using the MiniBEST Universal RNA Extraction Kit. Using PrimeScript TM RT Master Mix (Perfect read Time), reverse transcribing the extracted RNA into cDNA according to the following system and procedure:
reverse rotationThe recording system is specifically as follows: 4 μ L of 5 XPrimeScript RT Master Mix, 1 μ g RNA, up to 20 μ L dH 2 O。
The reaction was carried out at 37 ℃ for 15 minutes, at 85 ℃ for 5 seconds, and then stored at 4 ℃.
After diluting the cDNA by 50 times, real-time fluorescent quantitative PCR reaction was performed using the following primers, reaction system, program and calculation method.
The primer sequence comprises: the IL-6 primer sequence pair shown as Seq ID No.11 and Seq ID No. 12; a pair of TGF-. Beta.1 primer sequences as shown in Seq ID No.13 and Seq ID No. 14; the primer sequence pairs for beta-actin as shown in Seq ID No.15 and Seq ID No. 16.
The reaction system is as follows: mu.L of 5 × AceQ Universal SYBR qPCR Master Mix, 0.2. Mu.L Primer F, 0.2. Mu.L Primer R, 2. Mu.L cDNA and 2.6. Mu.L dH 2 O。
The amplification procedure was followed 5 minutes at 95 ℃ and 40 cycles at 10 seconds at 95 ℃ and 30 seconds at 60 ℃ and finally 5 seconds at 65 ℃ after 10 minutes at 95 ℃.
Data processing: use 2 -ΔΔCt The method of (4) calculating the expression amount. Namely, Δ Ct = Ct Target gene -Ct Reference gene ;ΔΔCt=ΔCt Experimental group -ΔCt Control group (ii) a Fold change =2 -ΔΔCt 。
As shown in FIG. 1, the N-glycosylation modified Ganoderma lucidum immunomodulatory proteins (N31S, T36N and N31S/T36N) significantly inhibited the expression of the proinflammatory mediator IL-6 gene and promoted the expression of the anti-inflammatory mediator TGF-. Beta.1, as compared to Ganoderma lucidum immunomodulatory protein (WT). Meanwhile, the result also shows that the effect of N31S/T36N is more obvious.
Example 3
Analysis of anti-inflammatory mechanism of N-glycosylation modified ganoderma lucidum immunomodulatory protein:
at 2X 10 5 Cell/well concentration cells were seeded into 24 well cell culture plates and cultured for 24h. The medium was discarded, and the medium containing the Ganoderma lucidum immunomodulatory protein and the N-glycosylation-modified Ganoderma lucidum immunomodulatory protein at a concentration of 10. Mu.g/mL were added, respectively, and the culture was continued for 24 hours. Wash cells with PBSAfter that, an appropriate amount of RIPA (Shanghai Biyuntian Biotechnology Co., ltd.) was added, and after whipping, it was centrifuged at 12,000 rpm for 10min at 4 ℃. The supernatant was collected, and the protein concentration was measured using the BCA method protein concentration measurement kit. Western Blot detection was performed using β -actin, p38 and phosphorylated p38 (p-p 38) antibodies (Abcam) as primary antibodies and goat anti-mouse and goat anti-rabbit IgG labeled with horseradish peroxidase (HRP) (Biotechnology engineering (Shanghai) Co., ltd.) as secondary antibodies. The results are shown in fig. 2, compared with ganoderma lucidum immunomodulatory protein (WT), N-glycosylation modified ganoderma lucidum immunomodulatory protein (N31S, T36N and N31S/T36N) can significantly interfere with phosphorylation of p38, thereby inhibiting p38 MAPK signaling pathway. Meanwhile, the effect of N31S/T36N is more obvious.
The invention transforms the ganoderma lucidum immunomodulatory protein through an in vitro mutation technology to obtain the N-glycosylation modified ganoderma lucidum immunomodulatory protein, and compared with the ganoderma lucidum immunomodulatory protein, the N-glycosylation modified ganoderma lucidum immunomodulatory protein has more remarkable biological activity, more excellent anti-inflammatory effect and lower cytotoxicity.
The foregoing embodiments may be modified in many different ways by one skilled in the art without departing from the spirit and scope of the invention, which is defined by the appended claims and not by the preceding embodiments, and all embodiments within their scope are intended to be limited by the scope of the invention.
Sequence listing
<110> Tibet ananda biopharmaceutical science, limited liability company
Application of <120> N-glycosylation modified ganoderma lucidum immunomodulatory protein
<130> fnc283e
<141> 2020-12-16
<160> 21
<170> SIPOSequenceListing 1.0
<210> 1
<211> 111
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Met Ser Asp Thr Ala Leu Ile Phe Arg Leu Ala Trp Asp Val Lys Lys
1 5 10 15
Leu Ser Phe Asp Tyr Thr Pro Asn Trp Gly Arg Gly Asn Pro Ser Asn
20 25 30
Phe Ile Asp Thr Val Thr Phe Pro Lys Val Leu Thr Asp Lys Ala Tyr
35 40 45
Thr Tyr Arg Val Ala Val Ser Gly Arg Asn Leu Gly Val Lys Pro Ser
50 55 60
Tyr Ala Val Glu Ser Asp Gly Ser Gln Lys Val Asn Phe Leu Glu Tyr
65 70 75 80
Asn Ser Gly Tyr Gly Ile Ala Asp Thr Asn Thr Ile Gln Val Phe Val
85 90 95
Val Asp Pro Asp Thr Asn Asn Asp Phe Ile Ile Ala Gln Trp Asn
100 105 110
<210> 2
<211> 111
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Met Ser Asp Thr Ala Leu Ile Phe Arg Leu Ala Trp Asp Val Lys Lys
1 5 10 15
Leu Ser Phe Asp Tyr Thr Pro Asn Trp Gly Arg Gly Asn Pro Asn Asn
20 25 30
Phe Ile Asp Asn Val Thr Phe Pro Lys Val Leu Thr Asp Lys Ala Tyr
35 40 45
Thr Tyr Arg Val Ala Val Ser Gly Arg Asn Leu Gly Val Lys Pro Ser
50 55 60
Tyr Ala Val Glu Ser Asp Gly Ser Gln Lys Val Asn Phe Leu Glu Tyr
65 70 75 80
Asn Ser Gly Tyr Gly Ile Ala Asp Thr Asn Thr Ile Gln Val Phe Val
85 90 95
Val Asp Pro Asp Thr Asn Asn Asp Phe Ile Ile Ala Gln Trp Asn
100 105 110
<210> 3
<211> 111
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Met Ser Asp Thr Ala Leu Ile Phe Arg Leu Ala Trp Asp Val Lys Lys
1 5 10 15
Leu Ser Phe Asp Tyr Thr Pro Asn Trp Gly Arg Gly Asn Pro Ser Asn
20 25 30
Phe Ile Asp Asn Val Thr Phe Pro Lys Val Leu Thr Asp Lys Ala Tyr
35 40 45
Thr Tyr Arg Val Ala Val Ser Gly Arg Asn Leu Gly Val Lys Pro Ser
50 55 60
Tyr Ala Val Glu Ser Asp Gly Ser Gln Lys Val Asn Phe Leu Glu Tyr
65 70 75 80
Asn Ser Gly Tyr Gly Ile Ala Asp Thr Asn Thr Ile Gln Val Phe Val
85 90 95
Val Asp Pro Asp Thr Asn Asn Asp Phe Ile Ile Ala Gln Trp Asn
100 105 110
<210> 4
<211> 39
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ccgccgccgg aattcatgtc tgacaccgct ttgatcttc 39
<210> 5
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
gaagttagat gggttacctc ttccc 25
<210> 6
<211> 49
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
gggaagaggt aacccatcta acttcatcga caccgttacc ttcccaaag 49
<210> 7
<211> 40
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
atgatgatgg ggcccgttcc attgagcaat gatgaagtcg 40
<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
gaagttgttt gggttacctc ttccc 25
<210> 9
<211> 49
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gggaagaggt aacccaaaca acttcatcga caacgttacc ttcccaaag 49
<210> 10
<211> 49
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
gggaagaggt aacccatcta acttcatcga caacgttacc ttcccaaag 49
<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
catgttctct gggaaatcgt gg 22
<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
aacgcactag gtttgccgag ta 22
<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
acagcaccaa ttgtccaagt ttc 23
<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
cggtgcatgc atagccttgt 20
<210> 15
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
atcgtgcggg acatcaagg 19
<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
tcgttgccga tggtgatgac 20
<210> 17
<211> 111
<212> PRT
<213> N-glycosylation modified immunomodulatory protein (Artificial Sequence) of Ganoderma lucidum
<400> 17
Met Ser Asp Thr Ala Leu Ile Phe Arg Leu Ala Trp Asp Val Lys Lys
1 5 10 15
Leu Ser Phe Asp Tyr Thr Pro Asn Trp Gly Arg Gly Asn Pro Asn Asn
20 25 30
Phe Ile Asp Thr Val Thr Phe Pro Lys Val Leu Thr Asp Lys Ala Tyr
35 40 45
Thr Tyr Arg Val Ala Val Ser Gly Arg Asn Leu Gly Val Lys Pro Ser
50 55 60
Tyr Ala Val Glu Ser Asp Gly Ser Gln Lys Val Asn Phe Leu Glu Tyr
65 70 75 80
Asn Ser Gly Tyr Gly Ile Ala Asp Thr Asn Thr Ile Gln Val Phe Val
85 90 95
Val Asp Pro Asp Thr Asn Asn Asp Phe Ile Ile Ala Gln Trp Asn
100 105 110
<210> 18
<211> 333
<212> DNA
<213> Pichia pastoris preferred codons (Pichia pastoris Artificial Sequence)
<400> 18
atgtctgaca ccgctttgat cttcagactg gcttgggacg tcaagaagtt gtccttcgac 60
tacaccccaa actggggaag aggtaaccca aacaacttca tcgacaccgt taccttccca 120
aaggtcttga ctgacaaggc ctacacctac agagttgccg tttctggtcg taacctgggt 180
gtcaagccat cctacgctgt tgagtccgac ggttcccaga aggtcaactt cttggagtac 240
aactctggtt acggtatcgc tgacactaac accatccaag ttttcgttgt cgacccagac 300
accaacaacg acttcatcat tgctcaatgg aac 333
<210> 19
<211> 333
<212> DNA
<213> N-glycosylation modified N31S gene (Artificial Sequence) of immunomodulating protein of Ganoderma lucidum
<400> 19
atgtctgaca ccgctttgat cttcagactg gcttgggacg tcaagaagtt gtccttcgac 60
tacaccccaa actggggaag aggtaaccca tctaacttca tcgacaccgt taccttccca 120
aaggtcttga ctgacaaggc ctacacctac agagttgccg tttctggtcg taacctgggt 180
gtcaagccat cctacgctgt tgagtccgac ggttcccaga aggtcaactt cttggagtac 240
aactctggtt acggtatcgc tgacactaac accatccaag ttttcgttgt cgacccagac 300
accaacaacg acttcatcat tgctcaatgg aac 333
<210> 20
<211> 333
<212> DNA
<213> N-glycosylation modified T36N gene (Artificial Sequence)
<400> 20
atgtctgaca ccgctttgat cttcagactg gcttgggacg tcaagaagtt gtccttcgac 60
tacaccccaa actggggaag aggtaaccca aacaacttca tcgacaacgt taccttccca 120
aaggtcttga ctgacaaggc ctacacctac agagttgccg tttctggtcg taacctgggt 180
gtcaagccat cctacgctgt tgagtccgac ggttcccaga aggtcaactt cttggagtac 240
aactctggtt acggtatcgc tgacactaac accatccaag ttttcgttgt cgacccagac 300
accaacaacg acttcatcat tgctcaatgg aac 333
<210> 21
<211> 333
<212> DNA
<213> N-glycosylation modified N31S/T36N gene (Artificial Sequence)
<400> 21
atgtctgaca ccgctttgat cttcagactg gcttgggacg tcaagaagtt gtccttcgac 60
tacaccccaa actggggaag aggtaaccca tctaacttca tcgacaacgt taccttccca 120
aaggtcttga ctgacaaggc ctacacctac agagttgccg tttctggtcg taacctgggt 180
gtcaagccat cctacgctgt tgagtccgac ggttcccaga aggtcaactt cttggagtac 240
aactctggtt acggtatcgc tgacactaac accatccaag ttttcgttgt cgacccagac 300
accaacaacg acttcatcat tgctcaatgg aac 333
Claims (4)
1. A preparation method of ganoderma lucidum immunomodulatory protein based on N-glycosylation modification is characterized in that based on amino acid sequence of ganoderma lucidum immunomodulatory protein shown in Seq ID No.17, gene synthesis is carried out by referring to preferred codon of Pichia pastoris (Pichia pastoris) shown in Seq ID No.18, and the method comprises the following steps:
(1) obtaining the N-glycosylation modified ganoderma lucidum immunomodulatory protein N31S gene shown in Seq ID No.19 by the primers shown in Seq ID No. 4-7; or by
(2) Obtaining the N-glycosylation modified ganoderma lucidum immunomodulatory protein T36N gene shown in Seq ID No.20 by using the primers shown in Seq ID No.4, seq ID No.8, seq ID No.9 and Seq ID No. 7; or by
(3) Obtaining N-glycosylation modified ganoderma lucidum immunomodulatory protein N31S/T36N gene shown in Seq ID No.21 by primers shown in Seq ID No.4, seq ID No.5, seq ID No.10 and Seq ID No. 7;
then cloning the N31S gene, the T36N gene and the N31S/T36N gene to a eukaryotic expression vector pPIC 9K: X-His respectively, then transforming Pichia pastoris GS115 respectively to obtain yeast transformants, and finally obtaining recombinant protein through methanol induction;
the N-glycosylation modified ganoderma lucidum immunomodulatory protein is derived from a pichia pastoris expression system, and the amino acid sequence of the N-glycosylation modified ganoderma lucidum immunomodulatory protein is shown as Seq ID No.1, seq ID No.2 and Seq ID No. 3;
the Ganoderma lucidum immunomodulatory protein is selected from Ganoderma lucidum (Ganoderma lucidum), ganoderma tsugae (Ganoderma tsugae), ganoderma sinense (Ganoderma japonicum), ganoderma japonicum (Ganoderma japonicum), ganoderma microsporum (Ganoderma microsporum), ganoderma sinense (Ganoderma sinense), ganoderma atrum (Ganoderma atrum), ganoderma applanatum (Ganoderma applanatum) or Ganoderma pseudoantler (Ganoderma amboinense).
2. The method of claim 1, wherein the primers are specifically: seq ID No.4:5 'ccgccgccggaaattcatgtctgacacaccgcttttgatctc-3', seq ID No.5:5 'gaagttagatggttacccttcttccc-3', seq ID No.6:5 'gggaaggtaacccatctataactttcaaag-3', seq ID No.7:5 'atgatgatgggccgtccattgagcaatgatgaagtcg-3', seq ID No.8:5 'gaagttgtttgggttacccttcttccc-3', seq ID No.9:5 'gggaaggtaacccaaacaacttcatcatcgacaacacgtacttcccaaag 3', seq ID No.10:5 'gggaaggtaaccctacttcatcatcaacgttaccctcccaaag-3'.
3. Use of an N-glycosylation modified ganoderma lucidum immunomodulatory protein, prepared according to claim 1 or 2, for the preparation of an anti-inflammatory medicament for inhibiting the p38 MAPK pathway in a cell and decreasing expression of pro-inflammatory mediators.
4. The use of claim 3, wherein said cells comprise mouse peritoneal macrophage RAW264.7.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011523442.6A CN112516288B (en) | 2020-12-22 | 2020-12-22 | Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011523442.6A CN112516288B (en) | 2020-12-22 | 2020-12-22 | Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112516288A CN112516288A (en) | 2021-03-19 |
CN112516288B true CN112516288B (en) | 2023-04-18 |
Family
ID=75002160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011523442.6A Active CN112516288B (en) | 2020-12-22 | 2020-12-22 | Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112516288B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112625097B (en) * | 2019-08-27 | 2022-02-08 | 上海交通大学 | Ganoderma lucidum immunomodulatory protein mutant and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2611540A1 (en) * | 2007-11-09 | 2009-05-09 | Nipro Corporation | Sugar chain-containing albumin as a drug carrier to the liver |
CN103524628A (en) * | 2013-10-15 | 2014-01-22 | 张喜田 | Recombinant ganoderma lucidum immunoregulatory protein, human serum albumin fusion protein, and preparation method and application thereof |
CN110563822A (en) * | 2019-08-27 | 2019-12-13 | 上海交通大学 | Ganoderma lucidum immunomodulatory protein mutant and application thereof |
CN111329808A (en) * | 2020-04-03 | 2020-06-26 | 西安力邦医美科技有限公司 | Cosmetic composition with anti-glycosylation and anti-aging effects and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
CN105188767A (en) * | 2012-07-25 | 2015-12-23 | 布罗德研究所有限公司 | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
TWI589586B (en) * | 2014-03-04 | 2017-07-01 | 善笙生物科技股份有限公司 | Uses of starch binding protein (sbp)-tagged immunostimulatory protein |
CN107501405B (en) * | 2017-09-25 | 2020-12-25 | 江苏护理职业学院 | Autophagy inhibiting polypeptide |
CN108546287A (en) * | 2018-04-16 | 2018-09-18 | 上海市农业科学院 | A kind of antitumor fungal immunomodulatory protein Fip-bbo and its application |
-
2020
- 2020-12-22 CN CN202011523442.6A patent/CN112516288B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2611540A1 (en) * | 2007-11-09 | 2009-05-09 | Nipro Corporation | Sugar chain-containing albumin as a drug carrier to the liver |
CN103524628A (en) * | 2013-10-15 | 2014-01-22 | 张喜田 | Recombinant ganoderma lucidum immunoregulatory protein, human serum albumin fusion protein, and preparation method and application thereof |
CN110563822A (en) * | 2019-08-27 | 2019-12-13 | 上海交通大学 | Ganoderma lucidum immunomodulatory protein mutant and application thereof |
CN111329808A (en) * | 2020-04-03 | 2020-06-26 | 西安力邦医美科技有限公司 | Cosmetic composition with anti-glycosylation and anti-aging effects and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112516288A (en) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114591923B (en) | Cannabidiol synthetase mutant and construction method and application thereof | |
CN112516288B (en) | Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein | |
CN107245108A (en) | Bovine albumin interferon-' alpha ' interleukin-22 fusion protein, preparation method and its encoding gene, a kind of ox long-acting interferon | |
CN112646009B (en) | Ganoderma lucidum immunomodulatory protein mutant and application thereof | |
CN107266587A (en) | A kind of recombinant bovine long-acting interferon α and prepare fusion protein of this long-acting interferon and preparation method thereof | |
CN107936107B (en) | Ostrea gigas interferon regulatory factor CgIRF-1 gene recombinant protein, preparation method and application | |
CN109890837B (en) | High stability and high affinity DMIC and its preparing process | |
CN114262368B (en) | Preparation method of recombinant Scl2 collagen and variable-speed hydrogel thereof | |
CN114262382A (en) | Bispecific antibodies and uses thereof | |
CN107434826B (en) | Yeast cell for high expression of Slit2D2-HSA protein and application | |
CN107245110A (en) | A kind of fusion protein being made up of sheep albumin, sheep interferon gamma and sheep interferon-tau and preparation method thereof | |
CN108794644A (en) | A kind of fusion protein and preparation method thereof being made of cattle interleukins-2 2, Bov IFN γ and Bov IFN α | |
CN107365390A (en) | A kind of fusion protein being made up of pig albumin, Porcine interferon-gamma and pig interleukin 2 and 6 and preparation method thereof | |
CN108794645A (en) | A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α | |
CN108840953A (en) | A kind of fusion protein and preparation method thereof being made of sheep interleukin 2, sheep interferon gamma and sheep interferon-tau | |
CN116143899B (en) | Recombinant antimicrobial peptide pANG4 and preparation method and application thereof | |
CN107383202A (en) | A kind of fusion protein being made up of OVA, chicken interferon gamma and recombinant chIL-2 and preparation method thereof | |
CN107253997A (en) | A kind of recombinant bovine long-acting interferon and prepare fusion protein of this long-acting interferon and preparation method thereof | |
CN112877335B (en) | Portunus trituberculatus angiogenin PtANG gene and coding protein and application thereof | |
CN114409800B (en) | Method for preparing recombinant cystatin C | |
CN116333070A (en) | Preparation method and application of Tibetan ganoderma lucidum immunomodulatory protein | |
CN107266589A (en) | A kind of fusion protein being made up of dog albumin, dog interferon γ and canine leucocyte interleukin 2 and preparation method thereof | |
CN107266590A (en) | A kind of fusion protein being made up of dog albumin, dog interferon γ and dog interferon alpha and preparation method thereof | |
CN116426545A (en) | Recombinant pyranose oxidase, and preparation method and application thereof | |
CN116410993A (en) | Recombinant lactic dehydrogenase and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |